Press release
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
- Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively -\n\n- Gossamer Announces Seralutinib Open Label Extension Data in PAH Patients -\n\n- Gossamer to Discontinue Clinical Development of GB1275 - \n\n- Cash, cash equivalents and marketable securities totaled $406 million as of June 30, 2021 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter of 2021 and provided a corporate update.\n\n“I am tremendously proud of the dedication and perseverance the Gossamer team has shown this year, pressing forward with the execution of two Phase 2 studies for our lead clinical programs, seralutinib and GB004, in the face of operational challenges presented by the pandemic,” said Faheem Hasnain, Co-Founder, Chairman and Chief Executive Officer of Gossamer. “We are also very happy to share data from the first extended clinical experience of seralutinib, the first such data from an inhaled kinase inhibitor in patients with PAH. Though the pandemic limited the number of patients who were able to continue onto the OLE, these patient experiences provide additional evidence supporting the potential of seralutinib to improve the lives of PAH patients.”\n\nClinical-Stage Product Candidate Updates\n\nSeralutinib (GB002): Inhaled PDGFR, CSF1R and C-KIT Inhibitor for PAH\n\n\nWhile the conduct of the Phase 1b study of seralutinib in patients with Functional Class II and III PAH was interrupted by the COVID-19 pandemic, two of the eight patients that completed the two-week Phase 1b study were also able to complete the optional 6-month open-label extension period.\n\n\nBoth patients entered and completed the extension study on three classes of background therapy, including oral prostacyclins.\n\n\nNo serious adverse events were reported, and no safety concerns identified with longer term treatment over a six-month period at a twice daily 90mg dose.\n\n\nIn both patients, decreases in NT-proBNP, a biomarker for right heart strain, and increases in six-minute walk distance,...